Stemline Therapeutics Announces Multiple Preclinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 5, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), announced today that results from multiple ongoing preclinical studies were selected for presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2014 at the Moscone Center, San Francisco, CA. Investigators will present data on Stemline's portfolio of therapeutics that target the interleukin-3 receptor (IL-3R), which is overexpressed on tumor bulk and cancer stem cells (CSCs) of a wide variety of hematologic malignancies.

"We have validated IL-3R as a target in patients with various hematologic malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML)," commented Eric K. Rowinsky, M.D., Chief Medical Officer and Head of Research and Development at Stemline. He added, "The IL-3R is overexpressed on both cancer stem cells and mature malignant cells relative to their nonmalignant counterparts, and is also present on nonmalignant plasmacytoid dendritic cells (pDCs), which stimulate the growth of hematologic malignancies, such as multiple myeloma. Stemline is developing a panoply of IL-3R-directed therapeutics, including SL-401, SL-501, and SL-101 to treat IL-3R-overexpressing cancers, as well as malignancies driven by pDCs. Furthermore, pDCs have been demonstrated to play a role in several autoimmune diseases, including systemic lupus erythematosus and scleroderma, and we are developing a foundation for evaluating Stemline's IL-3R directed therapies in patients with these autoimmune diseases."

Preclinical data on SL-401, SL-501, and SL-101 to be presented at the 2014 ASH meeting .

Stemline's most advanced candidate, SL-401, is a clinical stage therapeutic currently in two multicenter, open-label clinical trials. The first trial is actively enrolling patients with BPDCN and relapsed/refractory AML, whereas the second trial is open for AML patients in first complete remission (CR) following induction chemotherapy, but display evidence of minimal residual disease (MRD) in their bone marrow and remain at high risk for relapse. Stemline is also planning additional clinical trials in other IL-3R+ indications. At ASH, Arghya Ray, Ph.D., of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute, Boston, MA, will present several lines of evidence demonstrating that SL-401 blocks pDC-triggered growth of myeloma cells, inhibits the development of osteoclasts responsible for bone resorption in myeloma patients, and limits the viability of CSC-like MM cells.

Janice Chen, Ph.D., of Stemline Therapeutics, will present preclinical data on SL-501, a next generation, rationally designed variant of SL-401 that binds to IL-3R with high affinity and has shown enhanced potency against hematologic cancer cells in both in vitro and in vivo xenograft experiments. Dr. Chen's presentation will highlight the antitumor activity of SL-501 against Hodgkin's and non-Hodgkin's lymphoma.

Additionally, Lina Han, Ph.D., of the Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Andersen Cancer Center, Houston, TX, will present the results of preclinical studies detailing the activity of SL-101 in AML, as well as its mechanisms of action. SL-101, a next generation IL-3R targeted therapy, is a novel antibody-drug conjugate that targets the alpha chain of IL-3R (CD123). SL-101 has demonstrated preclinical activity against a variety of cancer types. Additional accepted abstracts include results from studies demonstrating IL-3R expression on certain myeloproliferative disorders and SL-401 activity against hairy cell leukemia.

Details on the presentations are as follows:

SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis
Lead Author: Arghya Ray, Ph.D., The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Abstract Number: 3441
Date and Time: Sunday, December 7, 2014 at 6:00-8:00 PM PT
Location: West Building, Level 1 (Moscone Center)

SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's and Non-Hodgkin's Lymphoma
Lead Author: Janice Chen, Ph.D., Stemline Therapeutics, New York, NY
Abstract Number: 4500
Date and Time: Monday, December 8, 2014 at 6:00-8:00 PM PT
Location: West Building, Level 1 (Moscone Center)

Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia
Lead Author: Lina Han, Ph.D., Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Andersen Cancer Center, Houston, TX
Abstract Number: 981
Date and Time: Saturday, December 6, 2014 at 5:30-7:30 PM PT
Location: North Building, Hall E (Moscone Center)

Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms
Lead Author: Terra Lasho, Ph.D., Division of Hematology, Mayo Clinic, Rochester, MN
Abstract Number: 71457
Published online through ASH abstracts site

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia
Lead Author: Christopher Brooks, Ph.D., Stemline Therapeutics, New York, NY
Abstract Number: 5663
Published online through ASH abstracts site

A copy of the above referenced abstracts can be viewed online through the ASH website at www.hematology.org .

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinical stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R). A multicenter clinical trial with SL-401 is currently open and accruing patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced acute myeloid leukemia (AML). An additional clinical trial with SL-401 is currently open in patients with AML who are in first complete remission (CR) with minimal residual disease (MRD), which is associated with a high relapse rate. Stemline is also planning SL-401 trials in additional hematologic cancers including several uncommon, stem cell-derived myeloproliferative disorders. Previously, SL-401 demonstrated single-agent activity, including multiple durable CRs, in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML. SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open and accruing adult patients with glioblastoma multiforme (GBM) in first recurrence. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers. For more information about Stemline Therapeutics, visit www.stemline.com .

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our preclinical studies and clinical trials, including site initiation, internal review board approval, scientific review committee approval, and patient accrual; our plans to develop and commercialize our product candidates; our available cash; our ability to obtain and maintain intellectual property protection for our product candidates; the ability of our product candidates to successfully perform in clinical trials; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Investor Relations Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 326

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 0

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 117

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 419

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading

Top 5 Most Recently Viewed Articles

Inventiva's Significant Capital Boost Through Public Offering

Updated Category News Views 276

Inventiva's Upsized Public Offering Explained Inventiva, a clinical-stage biopharmaceutical company known for its focus on developing oral therapies targeting metabolic disorders, has recently announced the pricing details of its public offering. This significant initiative is set to raise around $150 million by selling approximately 38.96 million American Depositary...

Continue Reading
The Future of AI: How Innovations Drive Market Growth

Updated Category News Views 264

AI Market Growth Overview The artificial intelligence (AI) market is set for substantial growth, projected to increase by USD 237.4 billion from 2024 to 2028. The forecast indicates a remarkable compound annual growth rate (CAGR) of 30.07% during this period. This growth can largely be attributed to the rising demand for effective solutions in fraud prevention and the...

Continue Reading
commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
AKOOL's Agentic Canvas: AI Execution Revolution

Updated Category News Views 23

AKOOL Elevates AI from Chat to Execution Well, folks, it looks like AKOOL is shaking things up in the world of artificial intelligence. Forget about AI that's just about chatting away and searching for answers like a digital gopher. This time, AKOOL is bringing something new to the table with its Agentic Canvas, and it's a real game-changer for anyone still fooling around...

Continue Reading
Qudian Inc. Transitions to High Templar Tech Limited

Updated Category News Views 222

Qudian Inc. Transitions to High Templar Tech Limited Qudian Inc., a technology-driven consumer company in China, has officially announced its rebranding to High Templar Tech Limited along with a change in its stock ticker from "QD" to "HTT". This significant decision reflects the company's evolving strategy and commitment to enhancing consumer experiences through...

Continue Reading